Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF-MEK Inhibition Is Effective in BRAFV600E-Mutant Papillary Craniopharyngioma.

Cancer discovery - 6 Sept 2023

Abstract excerpt

Vemurafenib plus cobimetinib is effective in patients with BRAF-mutant papillary craniopharyngioma.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Craniopharyngioma
Share to Mitogen-Activated Protein Kinase Kinases
Share to Mutation
Share to Pituitary Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 37477404
DOI: 10.1158/2159-8290.CD-RW2023-116

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF-MEK Inhibition Is Effective in BRAFV600E-Mutant Papillary Craniopharyngioma.PMID 37477404Read ↗

BRAF plus MEK inhibition effective in papillary craniopharyngioma.Semantic proximity Read ↗

Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutationsSemantic proximity Read ↗

Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review.Semantic proximity Read ↗

Case report and literature review of BRAF-V600 inhibitors for treatment of papillary craniopharyngiomas: A potential treatment paradigm shift.Semantic proximity Read ↗

Case Report: Successful Use of BRAF/MEK Inhibitors in Aggressive BRAF-mutant Craniopharyngioma.Semantic proximity Read ↗

BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.Semantic proximity Read ↗

Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.Semantic proximity Read ↗

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngiomaSemantic proximity Read ↗

Targeted therapy in BRAF mutated aggressive papillary craniopharyngioma: a case report and overview of the literature.Semantic proximity Read ↗

Integrating Systemic Therapies into the Multimodality Therapy of Patients with Craniopharyngioma.Semantic proximity Read ↗

[Molecularly Targeted Therapy for Craniopharyngioma].Semantic proximity Read ↗

Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.